Table 2 |
||
|
Characteristics of the study sample |
||
| Variable |
Cases (n = 5,565) |
Controls (n = 55,650) |
|
|
||
| Age on index date (years): |
||
| 55 to 64 |
2,116 (38) |
21,160 (38) |
| 65 to 74 |
1,800 (32) |
18,000 (32) |
| 75 to 84 |
1,356 (24) |
13,560 (24) |
| ≥ 85 |
293 (5.3) |
2,930 (5.3) |
| Medical history, n (%): |
||
| Congestive heart failure |
160 (2.9) |
1,337 (2.4) |
| Atrial fibrillation/flutter |
224 (4.0) |
1,819 (3.3) |
| Prediagnosis mammographya |
||
| < 1 year: |
417 (81) |
84 (1.6) |
| 1 to < 2 years: |
3 (0.6) |
84 (1.6) |
| 2 to < 3 years: |
9 (1.7) |
84 (1.6) |
| ≥ 3 years: |
17 (3.3) |
130 (2.5) |
| Myocardial infarction |
123 (2.2) |
1,492 (2.7) |
| Chronic pulmonary disease |
334 (6.0) |
3,125 (5.6) |
| Peripheral vascular disease |
167 (3.0) |
1,563 (2.8) |
| Cerebrovascular disease |
275 (4.9) |
2,842 (5.1) |
| Lymphoma |
12 (0.2) |
155 (0.3) |
| Other solid tumor |
0 |
0 |
| Liver disease |
44 (0.8) |
403 (0.7) |
| Diabetes (type I or II) |
215 (3.9) |
1,706 (3.1) |
| Diabetes with end-organ complication |
85 (1.5) |
591 (1.1) |
| Renal disease |
35 (0.6) |
446 (0.8) |
| Other drug exposures, n (%): |
||
| Hormone replacement therapy |
2,062 (37) |
17,582 (32) |
| Anticoagulants |
231 (4.2) |
2,109 (3.8) |
| NSAIDs |
3,106 (56) |
29,964 (54) |
| Aspirin, low-dose (< 150 mg) |
205 (3.7) |
2,004 (3.6) |
| Aspirin, high-dose (≥ 150 mg) |
505 (9.1) |
4,878 (8.8) |
|
|
||
|
aScreening mammography data were only available from 2001 onwards. We restricted the mammography analysis to cases and controls with index dates after 1 January 2006, when screening mammography would have been most common in Denmark. Categories reflect time elapsed between most recent mammogram and index date; proportion denominators are the total number of cases (n = 516) or controls (n = 5,160) in the restricted data set. NSAID, non-steroidal anti-inflammatory drug. |
||
|
Ahern et al. Breast Cancer Research 2008 10:R102 doi:10.1186/bcr2205 |
||
